PharmaLeaders Publish New Report on CRO
GlobalData’s Industry Dynamics Team is pleased to announce the publication of its new PharmaLeaders report entitled: Contract Research Organizations Benchmark Report: Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs.
This report represents the Industry Dynamics Team’s first endeavor into covering the pharmaceutical outsourcing marketplace.
GlobalData’s Industry Analyst, and author of the research, Adam Dion explains:“The CRO Benchmark Report will be one of many reports the Industry Dynamics Team will publish related to the outsourcing marketplace as we expand our coverage across the pharmaceutical value-chain to include vendors that provide drug makers with strategic ancillary services.”
“Over time, these reports will cover contract manufacturers, API producers, cloud IT services, cold-chain transport, logistics and other reports related to the pharmaceutical outsourcing. We believe our coverage and analysis of these services will be essential to pharma and biotech clients as the need to develop strategic partnerships with third-party vendors has never been more important."
“The pharmaceutical industry is currently facing significant headwinds — the blockbuster era is over and drug development costs continue to skyrocket. To respond, industry executives are changing the way they approach virtually every aspect of their business, including how they can maximise their resources and, at the same time, enter into risk-sharing agreements with contractors to generate significant cost savings,” says Dion.
The CRO Benchmark Report applies GlobalData’s proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analysed based on financial performance, cost-containment, capital structure and firm utilisation to illustrate the different strategies these companies are using to gain a competitive advantage. In addition to the financial metrics, this report discusses trends impacting the CRO marketplace, along with partnering and acquisition activity, and operations strategy.
This report also provides a drill-down analysis of three service lines, and four geographies to examine each segment’s revenue and growth leaders. Lastly, this research provides GlobalData’s outlook on the CRO sector and each company’s future competitive position.
GlobalData’s Director of Industry Dynamics, Joshua Owide, explains how the analysis found in the PharmaLeaders series will help clients improve their understanding of the outsourcing marketplace and the positioning of leading players and emerging competition:“The ultimate goal of our PharmaLeaders report series is to distinguish those companies that are at the forefront in their sector, in terms of financial performance, commercial effectiveness, and corporate strategy, from those firms that are trailing behind. Our analysis explains what is driving this divergence which enables clients to formulate their own strategies and improve decision making.”
Owide says: “These reports provide invaluable insights into the environment in which companies operate in and the events that will impact their businesses in the future”.
GlobalData’s PharmaLeaders report series is targeted at both the scientific and investor communities. Clients that have leveraged these reports come from industry R&D and strategy teams, private equity and venture capital firms, and professional and financial services consultancies.
Companies Covered in this report: Accelovance, Accovion, AMRI, Aptuit, Asklep, BioRasi, Catalent, Charles River, Chiltern, Clinipace, ClinStar, CMIC, Covance, CromSource, DKSH, EPS Corporation, Frontage, Icon, INC Research, Novella Clinical, Novotech, Ockham, Octagon Research Solutions, Paragon Biomedical, Parexel, Patheon, Pharmaron, Pharm-Olam, PPD, PRA International, PSI, QPS, Quintiles, ReSearch Pharmaceutical Services, Synexus, Syngene, SynteractHCR, TFS International, and WuXi.
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke...
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance